Filing summary
Entity and period: The supplied filing is Tokai Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2017—not a filing by Eledon Pharmaceuticals, Inc. Investors should verify the issuer and ticker before relying on this summary.
Business context and reporting period
Tokai was a clinical-stage biopharmaceutical company focused on galeterone for prostate cancer and its androgen receptor degradation agent (ARDA) discovery program. After discontinuing its pivotal ARMOR3-SV Phase 3 trial in 2016 and reducing its workforce by approximately 60%, the company was evaluating development options and strategic alternatives. Its proposed acquisition of Otic Pharma was pending during the quarter.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 / comparator |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $0.306 million | $7.931 million |
| General and administrative expense | $3.586 million | $3.549 million |
| Total operating expenses | $3.892 million | $11.480 million |
| Net loss | $3.866 million | $11.426 million |
| Net loss per share, basic and diluted | $0.17 | $0.51 |
| Cash used in operating activities | $3.148 million | $9.740 million |
At March 31, 2017, cash and cash equivalents were $24.4 million, total assets $25.831 million, total liabilities $2.467 million, and stockholders’ equity $23.364 million. There were no marketable securities at quarter-end; $4.175 million matured during the quarter. The balance sheet reports $48,000 in long-term liabilities and no borrowings are described in the supplied text. The company reported an accumulated deficit of $173.263 million.
Operating cash use was partly offset by noncash charges and working-capital changes. Cash increased by $1.177 million in the quarter, mainly because of $4.175 million in security maturities and a $150,000 decrease in restricted cash—not because operations generated cash. No revenue or profit margins are meaningful given the absence of revenue and continuing losses.
Material changes versus the prior comparable period
- Research and development expense fell $7.625 million, principally following the ARMOR3-SV discontinuation and lower clinical-trial and manufacturing costs; the workforce reduction also lowered personnel costs.
- General and administrative expense was nearly flat overall, but professional and consulting fees increased $915,000, primarily due to Otic transaction advisory, legal and accounting costs and litigation. Personnel-related costs decreased $1.048 million.
- Net loss narrowed by $7.560 million, and operating cash use declined by $6.592 million year over year.
Outlook, risks, contingencies and unusual items
- Management estimated that March 31 cash would fund operations through at least the first half of 2018 only if there were no new clinical efforts and the Otic transaction was not completed. Further development of galeterone or ARDA would require substantial additional funding.
- The Otic transaction required stockholder approval and other closing conditions. Otic shareholders were expected to own approximately 60% of Tokai after closing (62% if specified Otic options and warrants were exercised). A separate agreement contemplated approximately $4 million in Tokai share purchases at $1.11 per share at closing, with another $3 million invested in Otic through warrant exercises. Completion was not assured.
- Tokai received a Nasdaq deficiency notice because its share price had remained below $1.00; it had until September 4, 2017 to regain compliance. A reverse stock split was proposed for stockholder approval.
- Multiple securities class actions alleged misleading disclosures concerning galeterone trials or the Otic transaction. The company disputed the allegations; it said potential losses could not be estimated. The California IPO-related case had been stayed. The company made supplemental Otic proxy disclosures while denying liability.
- The company recorded $500,000 of transaction-related strategic-advisor expense in Q1 for a fairness opinion; it said the related accrual should have been recorded at year-end 2016, but the correction was not material. Another $500,000 was due upon transaction consummation.
- Other commitments include office lease payments of $1.118 million through July 2018, plus license-related fees, milestones and potential royalties if applicable. No material off-balance-sheet arrangements were reported.
- Management said disclosure controls were effective at a reasonable assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing issuer: Tokai Pharmaceuticals, Inc., rather than Eledon Pharmaceuticals, Inc.
- Check the subsequent outcome of the Otic transaction, stockholder vote, related financing and proposed reverse split; these remained pending in this filing.
- Review the company’s post-quarter cash use and any revised runway or financing needs, especially if clinical development resumed.
- Track Nasdaq bid-price compliance and the status and potential financial impact of the securities litigation.
- Assess the latest development plans and available clinical data for galeterone and the ARDA program; the filing states that future plans were uncertain.